Promising Companies

Also showing items for Promising Research

 
Stock Quotes for Promising Companies top ^
  • Industry: Data Storage
  • Sector: Technology
  • Stock Style: Small Growth
Sign-up for 3057 investment picks

 
News Articles for Promising Companies top ^
2U's Charitable Initiative Reaffirms its Mission to Support Education Around the World LANDOVER, Md.
Sign-up for 2U, Inc. Teams Up With Pencils of Promise to Help Build Schools in Guatemala investment picks
2014/8/19
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1138833&ProfileId=051205&sourceType=1 ATLANTA, GA --
Sign-up for Fresh Promise Foods Update investment picks
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced the presentation of preclinical data demonstrating the promise of DCR-PH1, the Company’s therapeutic candidate for the treatment of primary hyperoxaluria type 1 (PH1), a rare inherited liver disorder that often results in progressive and severe kidney damage.
Sign-up for Researchers Demonstrate Promise of Dicerna Investigational Therapy in Preclinical Model of Primary Hyperoxaluria Type 1 (PH1) investment picks
2014/7/8
By Therese Poletti, MarketWatch SAN FRANCISCO (MarketWatch) -- Meet LEO -- a device that promises to help you avoid exercise injuries.
Sign-up for UPDATE: This device promises aging baby boomers injury-free exercise investment picks
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, today announced the publication of promising preclinical data demonstrating the application of the Company’s novel Gene Silencing Oligonucleotides (GSOs) to inhibit microRNAs implicated in neovascularization, a process that involves the proliferation of blood vessels in tissue and is crucial for recovery following cardiovascular events.
Sign-up for Idera Pharmaceuticals and Collaborators Publish Promising Preclinical Data Targeting microRNA with Gene Silencing Oligonucleotide Technology investment picks
2014/9/10
By James Marson in Moscow and Laurence Norman in Brussels Ukrainian President Petro Poroshenko said Wednesday that Russia had withdrawn most of its troops from eastern Ukraine, raising further hopes that a peace deal struck last week would stick.
Sign-up for Ukraine Promises More Autonomy for East -- Update investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0957236001&sourceType=1 http://www.ccnmatthews.com/logos/20110321-wabco200.jpg BRUSSELS, BELGIUM --
Sign-up for WABCO Expands Its Fleet Management Solutions Business With Major Deal in Saudi Arabia; Delivers on the Promise of Transics Acquisition investment picks
HILDEN , Germany , and MARSEILLE, France , July 24, 2014 /PRNewswire/ -- Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including next-generation sequencing (NGS) gene panels, for blood cancers Mutations of SF3B1 gene, to be targeted by new test, indicate favorable prognosis for patients with bone marrow disorders known as myelodysplastic syndromes QIAGEN sees potential for developing companion diagnostics to guide treatment with new anti-cancer compounds under development that target the SF3B1 gene QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has acquired an exclusive global license to the biomarker SF3B1 from the University of Tokyo .
Sign-up for QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Promising Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Prominent Companies  |  Next: Promising Research